Immatics: Multiple Clinical Catalysts In Q4'25 And 2026

Core Insights - Immatics N.V. is developing a cell therapy named Anzu-cel (anzutresgene autoleucel, IMA203) targeting melanoma and other potential cancers, which has the potential to generate hundreds of millions or more in annual revenue [1] Company Overview - The company has already produced some data regarding Anzu-cel, indicating progress in its development [1] Market Potential - The anticipated revenue from Anzu-cel suggests a significant market opportunity within the oncology sector [1]